The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration

Hormone Receptor (HR)‐discordance between primary breast cancer and metastasis is a known biological phenomenon. Discordance studies usually comprise a heterogeneous group of HR‐positive and negative patients and allow for the comparison of changes in HR‐status from the primary to the recurrent disease. However, in a clinical setting, the rate of estrogen receptor‐conversion following endocrine therapy with agents such as Tamoxifen (TAM) in estrogen receptor‐positive cancers is of primary interest as opposed to total receptor discordance.

• Publication year

  2021

• Venue

  Cancer Reports

• Publication date

  2021-06-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cnr2.1431PMID 34086424PMCID 8789621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration

  2021cited by this paper
• Estrogen receptor signaling mechanisms.

  2019cited by this paper
• AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019

  2019cited by this paper
• Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

  2018cited by this paper
• Precision Medicine in Hormone Receptor-Positive Breast Cancer

  2018cited by this paper
• Influences of adjuvant treatments in hormone receptor positive breast cancer on receptor conversion in recurrent breast cancer

  2018cited by this paper
• Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis

  2018cited by this paper
• 20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

  2017cited by this paper
• Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site

  2017cited by this paper
• Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

  2017cited by this paper
• Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

  2016cited by this paper
• Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

  2015cited by this paper
• Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

  2015cited by this paper
• Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.

  2014cited by this paper
• Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

  2012cited by this paper
• Mechanisms of endocrine resistance in breast cancer.

  2011cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Coprescription of tamoxifen and medications that inhibit CYP2D6.

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.

  2009cited by this paper
• Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

  2006cited by this paper
• Impact of metastatic estrogen receptor and progesterone receptor status on survival

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer.

  2004cited by this paper
• Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis.

  2004cited by this paper
• Expert Commentary.

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

  1998cited by this paper
• Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS).

  1993cited by this paper
• pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

  1991cited by this paper
• Multiple estrogen receptor assays in human breast cancer.

  1983cited by this paper
• Statistics at Square One

  1976cited by this paper

• Real-world application of 18F-FES PET/CT on HR + breast cancer patients with brain metastases.

  2025cites this paper
• Epigenetic Therapeutics: Reprogramming Triple-Negative Breast Cancer into Responsive Subtypes.

  2025cites this paper
• Hybrid [18F] Fluoroestradiol Brain PET/CT/MRI for Detection of Estrogen Receptor–Positive Intracranial Metastases Compared with MRI and Vertex-to-Below the Knees PET Imaging

  2025cites this paper
• Effect of adjuvant endocrine therapy: single-agent vs. switching on breast cancer-free and overall survival — a retrospective cohort study

  2025influential citation
• Breast biomarkers evolution between primary and distant metastasis: incidence and significance

  2024cites this paper
• Updates on the roles of epigenetics in the mechanism, diagnosis, and treatment of triple-negative breast cancer: A review

  2023cites this paper
• The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration

  2021cites this paper
• Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer

  2021cites this paper